Browsing by Author "Mesa, T."

Now showing 1 - 3 of 3
  • Thumbnail Image
    Item
    Estado epiléptico refractario en niños
    (2013) Mesa, T.; Cardoso, I.; Acevedo, K.; Hernández, Marta; Santín Amo, José María; Moya, P.; Godoy, J.; Castillo, Andrés; Soto, P.
  • No Thumbnail Available
    Item
    Lyme Borreliosis in Chile. Report of a child probably infected by imported pets
    (1996) Ribera M., M.; Abarca Villaseca, Katia; Prado D., P.; Lobos M., T.; Palacios F., O.; Ferrés G., M.; Mesa, T.; Vial C., P.
    Lyme disease, caused by the spirochete Borrelia burgdorferi, has several clinical manifestations and is transmitted to man by tick bites. In Chile and Latin America, several cases have been reported, but none with immnoblot confirmation or isolation of the infecting organism. We report a 9 year old boy consulting with bilateral facial palsy, polyradiculoneuritis with tetraparesis and meningeal irritation. Cerebrospinal fluid analysis showed increased protein concentration without pleocytosis and negative viral or bacterial cultures. IgM antibodies against Borrelia burgdorferi, were positive by ELISA and were confirmed by immunoblot at the Reference Laboratory of the University of Connecticut. The child had a recent contact with hamsters brought from Germany. The substantiation of Lyme disease existence in Chile should prompt the search and isolation of the causal agent.
  • No Thumbnail Available
    Item
    The direct costs of epilepsy in a Chilean population
    (REVISTA DE NEUROLOGIA, 2007) Mesa, T.; Mesa, J. T.; Guarda, J.; Mahaluf, F.; Pauchard, F.; Undurraga, F.; Asmad, C.; Silva, G.
    Introduction. Epilepsy Chilean prevalence is 17-21/1,000 inhabitants. In past years, there is concern for the high costs involved in its handling. Aim. To estimate the direct costs of treatment and handling in specific population with epilepsy. Patients and methods. It is a retrospective study, in 6 groups of people with epilepsy: recent diagnosis (RD), remission (R), occasional seizures (OS), active without resistance to drugs (AWRD), resistance to pharmacological treatment (RPT), and epilepsy surgery (S). Data and characteristics tabulation and economical study of each group were made, considering 1 year of treatment. A comparison was made between them and their average in relation to international data. Results. 293 patients. 52% male. 76% adults. 25% students. 55% focal seizures. Costs per group: (USD/patient/year): RD, 443; R, 316; OS, 430; AWRD, 711; RPT 946, S, 4,262. Direct average cost of treatment for epilepsy in this population: 615 USD/patient/year. Conclusions. When differentiating in groups of individuals with epilepsy, the highest average annual cost is in surgery and the lowest in remission. In all the groups, except for surgery one, the highest expense is in drugs (average 81%). In relation to other countries, our direct costs are 5 times lower than in some developed countries and 3.5 times higher than in other developing countries. This data is of interest to governmental and financial spheres, so to provide a better quality of life for people with epilepsy, lowering costs and fees for their treatment and contributing to epilepsy and surgery national programs.